SteelPeak Wealth LLC Has $337,000 Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

SteelPeak Wealth LLC cut its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 21.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,242 shares of the company’s stock after selling 1,970 shares during the quarter. SteelPeak Wealth LLC’s holdings in Twist Bioscience were worth $337,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience during the third quarter worth approximately $34,000. Signaturefd LLC lifted its position in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after buying an additional 306 shares in the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 3rd quarter valued at $95,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter. Finally, KBC Group NV increased its stake in shares of Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after acquiring an additional 1,226 shares during the last quarter.

Twist Bioscience Trading Up 3.3 %

NASDAQ:TWST opened at $51.14 on Friday. The firm has a market capitalization of $3.04 billion, a PE ratio of -14.21 and a beta of 1.85. Twist Bioscience Co. has a 1 year low of $27.41 and a 1 year high of $60.90. The firm’s fifty day simple moving average is $48.19 and its 200 day simple moving average is $46.41.

Insider Buying and Selling at Twist Bioscience

In other news, COO Patrick John Finn sold 2,422 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total transaction of $121,511.74. Following the completion of the transaction, the chief operating officer now directly owns 272,044 shares in the company, valued at $13,648,447.48. The trade was a 0.88 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Robert F. Werner sold 1,448 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total value of $64,580.80. Following the completion of the sale, the chief accounting officer now directly owns 45,620 shares of the company’s stock, valued at $2,034,652. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 89,801 shares of company stock worth $4,147,858 over the last ninety days. Company insiders own 3.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TWST. Scotiabank boosted their target price on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 19th. Wolfe Research began coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research report on Thursday, October 17th. TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Robert W. Baird raised their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.